ReviewJournal of autoimmunity2008
Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
Review in Journal of autoimmunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 70 citations in OpenAlex.
- Fetal liver CD34Stem cell research & therapy · 2024Article
- Graft-versus-Host Disease Modulation by Innate T Cells.International journal of molecular sciences · 2023Review
- Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT.Frontiers in immunology · 2023Review
- The role of AMP-activated protein kinase in GVHD-causing T cells.Immunometabolism (Cobham, Surrey) · 2022Review
- Characterization of a xenograft model for anti-CD19 CAR T cell studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells.JCI insight · 2021Article
- Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1Scientific reports · 2019Article
- Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy.Critical reviews in immunology · 2019Review
- Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights.Advances in experimental medicine and biology · 2016Review
- Article
- A methods paper that led to much more.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Induction of M2-like macrophages in recipient NOD-scid mice by allogeneic donor CD4(+)CD25(+) regulatory T cells.Cellular & molecular immunology · 2012Article
- Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011Article
- Successful modulation of type 2 diabetes in db/db mice with intra-bone marrow--bone marrow transplantation plus concurrent thymic transplantation.Journal of autoimmunity · 2010Article
- Challenges for the autoimmunologist.Clinical reviews in allergy & immunology · 2010Article
- Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.Nature reviews. Cancer · 2010Review
- Recent advances in the treatment of systemic sclerosis.Clinical reviews in allergy & immunology · 2009Review
- Perspectives on Regulatory T Cell Therapies.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2009Article
- Hunt for pluripotent stem cell -- regenerative medicine search for almighty cell.Journal of autoimmunity · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Allogeneic hematopoietic cell transplantation (HCT) is an increasingly widely used treatment modality in hematological malignancies. Alloreactivity mediated by donor T cells (and, in some settings, by donor natural killer cells) can produce durable immunologic control or eradication of residual malignancy after allogeneic HCT. However, graft-vs.-tumor (GVT) effects are variably effective and are often accompanied by deleterious alloreactivity against normal host tissue, manifesting as graft-vs.-host disease (GVHD). A major focus of current research in HCT is the separation of beneficial GVT effects from GVHD. Here we review a number of approaches currently under investigation to specifically augment GVT effects, including the identification of minor histocompatibility antigens (mHA), adoptive immunotherapy with tumor-specific or mHA-specific cytotoxic T lymphocytes, vaccination of the donor or recipient to stimulate tumor-specific immunity, and adoptive transfer of natural killer cells. In addition, we review strategies being investigated to specifically suppress GVHD while sparing GVT, including the manipulation and infusion of regulatory T cells, the use of novel pharmacologic and biologic agents, and the use of mesenchymal stem cells. Ultimately, advances in separation of GVT from GVHD will further enhance the potential of allogeneic HCT as a curative treatment for hematological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.